Management of haemolysis-induced hyperkalaemia in an extremely low birthweight infant exposed to maternal sulfasalazine
Sign Up to like & getrecommendations! Published in 2025 at "BMJ Case Reports"
DOI: 10.1136/bcr-2024-262380
Abstract: Sulfasalazine is a non-specific immunomodulator with haemolytic anaemia as a known side effect that crosses the placenta. We present a preterm neonate with cardiac arrhythmia secondary to hyperkalaemia in the setting of maternal sulfasalazine therapy.… read more here.
Keywords: sulfasalazine; hyperkalaemia; haemolysis induced; infant ... See more keywords